Diagnostic utility of serum TRACP5b for secondary osteoporosis in ankylosing spondylitis: a comparative cross-sectional study with primary osteoporosis and healthy controls - Summary - MDSpire
Advertisement
Diagnostic utility of serum TRACP5b for secondary osteoporosis in ankylosing spondylitis: a comparative cross-sectional study with primary osteoporosis and healthy controls
To evaluate serum TRACP5b levels in patients with primary osteoporosis and secondary osteoporosis due to ankylosing spondylitis, and to assess the diagnostic utility and clinical correlations of TRACP5b, including its relationship with disease activity and fracture risk.
Key Findings:
Serum TRACP5b levels were significantly elevated in AS patients compared to primary OP and healthy controls, indicating its potential as a diagnostic tool.
BMD was lower in AS patients, indicating a higher risk of fractures, which is critical for clinical management.
TRACP5b demonstrated potential as a biomarker for assessing bone resorption in AS, suggesting its utility in monitoring disease progression.
Interpretation:
Elevated TRACP5b levels in AS patients suggest its role as a reliable biomarker for secondary osteoporosis, reflecting ongoing bone remodeling processes that DXA may not capture, highlighting the need for additional diagnostic tools.
Limitations:
Small sample size may limit generalizability, suggesting caution in applying findings broadly.
Cross-sectional design does not establish causality, indicating the need for longitudinal studies.
Conclusion:
Serum TRACP5b is a promising diagnostic marker for secondary osteoporosis in ankylosing spondylitis, warranting further investigation in larger cohorts to validate its clinical utility.
